Investor Presentation First Nine Months of 2022
99
Investor presentation First nine months of 2022
Novo NordiskⓇ
In phase 2, semaglutide showed significant improvements in
NASH resolution
Semaglutide showed resolution of NASH with no worsening of
fibrosis versus placebo in the phase 2 trial¹
Proportion of patients
100%
Semaglutide showed numerical improvements in fibrosis and fewer
patients had progression of fibrosis vs placebo in phase 2 trial¹
Proportion of patients with
improvements in fibrosis
100%
Proportion of patients with
progression of fibrosis
100%
80%
60%
40%
22.9%
20%
*
*
47.3%
46.9%
0%
Placebo
0.1 mg
0.2 mg
semaglutide once-daily
80%
*
66.7%
80%
60%
60%
47.3%
47.8%
40%
35.9%
34.3%
40%
21.4%
20%
20%
10.8% 9.4%
*
5.8%
0%
0%
0.4 mg
Placebo 0.1 mg 0.2 mg 0.4 mg
Placebo 0.1 mg 0.2 mg 0.4 mg
semaglutide once-daily
semaglutide once-daily
Note: *statistically significant at 72 weeks (p<0.05 vs placebo). ¹Based on a complete case analysis, using people with an evaluable biopsy at end of trial. Analysis included patients with fibrosis stage 1, 2, or 3 at baseline. Data is from the semaglutide in NASH
phase 2 trial.
NASH: non-alcoholic steatohepatitisView entire presentation